Jove
Visualize
Contact Us

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Cutaneous Leishmaniasis with Liposomal Amphotericin B in the Elderly: A Randomized Clinical Trial.

The American journal of tropical medicine and hygiene·2025
Same author

The <i>Leishmania</i> Skin Test Predicts Clinic-Immunologic and Therapeutic Outcomes in Cutaneous Leishmaniasis.

Pathogens (Basel, Switzerland)·2024
Same author

Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2024
Same author

Improved Treatment Outcome Following the Use of a Wound Dressings in Cutaneous Leishmaniasis Lesions.

Pathogens (Basel, Switzerland)·2024
Same author

Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania (Viannia) braziliensis</i>.

Pathogens (Basel, Switzerland)·2024
Same author

Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.

Emerging infectious diseases·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 25, 2026

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Miltefosine and cutaneous leishmaniasis.

Paulo R L Machado1, Gerson Penna

  • 1Serviço de Imunologia, Complexo Hospitalar Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia. prlmachado@hotmail.com

Current Opinion in Infectious Diseases
|January 18, 2012
PubMed
Summary

Miltefosine offers a new oral treatment for leishmaniasis, showing promise in clinical trials for both New and Old World cutaneous forms, including severe cases. Further research is needed to fully establish its role in endemic regions.

More Related Videos

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Related Experiment Videos

Last Updated: May 25, 2026

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
12:22

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Area of Science:

  • Infectious Diseases
  • Tropical Medicine
  • Pharmacology

Background:

  • Leishmaniasis remains a significant global health challenge, particularly in its cutaneous forms.
  • Traditional treatments for leishmaniasis often involve parenteral administration, posing logistical challenges in endemic areas.
  • Miltefosine represents a novel therapeutic option for leishmaniasis.

Purpose of the Study:

  • To review and discuss the evidence for miltefosine's efficacy in treating New and Old World cutaneous leishmaniasis.
  • To evaluate the advantages of oral miltefosine compared to existing parenteral treatments.
  • To highlight the need for continued clinical research in leishmaniasis treatment.

Main Methods:

  • Systematic review of available clinical trial data on miltefosine for leishmaniasis.
  • Analysis of treatment outcomes in patients with various forms of cutaneous leishmaniasis.
  • Comparative assessment of miltefosine's administration route and patient accessibility.

Main Results:

  • Miltefosine is currently undergoing evaluation through small clinical trials, primarily in South America and Iran.
  • Successful treatment outcomes have been reported for severe forms of cutaneous leishmaniasis using miltefosine.
  • Oral administration of miltefosine presents a significant advantage for large-scale use in remote, endemic regions.

Conclusions:

  • Miltefosine has demonstrated activity in treating cutaneous leishmaniasis, including severe and refractory cases.
  • Its oral formulation offers a practical alternative to parenteral therapies, enhancing accessibility in endemic areas.
  • Increased investment in clinical research is crucial to fully understand and optimize miltefosine's role in leishmaniasis management.